Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neeraj Narula

Showing results (111-120 of 204) with videos related to

Pageof 21
Sort By:
European Journal of Gastroenterology & Hepatology|December 4, 2025
Patients with ulcerative colitis that have endoscopic Mayo score 1 and active histologic inflammation have similar outcomes to mild-moderate patients with Mayo score 2: a post hoc analysis of the VARSITY trialEmily C L Wong, Nazmus Khan, Parambir S Dulai, et al.
The American Journal of Gastroenterology|February 2, 2026
Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic DiseaseEmily C L Wong, Vipul Jairath, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|January 8, 2019
Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel DiseaseNeeraj Narula, Maria Ines Pinto-Sanchez, Natalia Causada Calo, et al.
Scandinavian Journal of Gastroenterology|June 24, 2020
Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel diseaseNeil K Sengupta, Ahmad Azizov, Smita Halder, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's DiseaseMohammad Shehab, Fatema Alrashed, Abdulrahman Alrashidi, et al.
Journal of Crohn'S & Colitis|November 12, 2024
Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND TrialEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
The American Journal of Gastroenterology|February 10, 2016
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to SteroidsNeeraj Narula, John K Marshall, Jean-Frederic Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 25, 2024
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysisMohammad Shehab, Fatema Alrashed, Abdulwahab Alsayegh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 23, 2021
ReplyEmily C L Wong, Jean-Frederic Colombel, Robert Riddell, et al.
Journal of Crohn'S & Colitis|November 27, 2020
End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's DiseaseEmily C L Wong, Elisa Buffone, So Jeong Lee, et al.
Pageof 21

Showing results (111-120 of 204) with videos related to

Sort By:
Pageof 21
European Journal of Gastroenterology & Hepatology|December 4, 2025
Patients with ulcerative colitis that have endoscopic Mayo score 1 and active histologic inflammation have similar outcomes to mild-moderate patients with Mayo score 2: a post hoc analysis of the VARSITY trialEmily C L Wong, Nazmus Khan, Parambir S Dulai, et al.
The American Journal of Gastroenterology|February 2, 2026
Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic DiseaseEmily C L Wong, Vipul Jairath, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|January 8, 2019
Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel DiseaseNeeraj Narula, Maria Ines Pinto-Sanchez, Natalia Causada Calo, et al.
Scandinavian Journal of Gastroenterology|June 24, 2020
Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel diseaseNeil K Sengupta, Ahmad Azizov, Smita Halder, et al.
Alimentary Pharmacology & Therapeutics|July 28, 2025
Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's DiseaseMohammad Shehab, Fatema Alrashed, Abdulrahman Alrashidi, et al.
Journal of Crohn'S & Colitis|November 12, 2024
Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND TrialEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
The American Journal of Gastroenterology|February 10, 2016
Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to SteroidsNeeraj Narula, John K Marshall, Jean-Frederic Colombel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 25, 2024
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysisMohammad Shehab, Fatema Alrashed, Abdulwahab Alsayegh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 23, 2021
ReplyEmily C L Wong, Jean-Frederic Colombel, Robert Riddell, et al.
Journal of Crohn'S & Colitis|November 27, 2020
End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's DiseaseEmily C L Wong, Elisa Buffone, So Jeong Lee, et al.
Pageof 21